Effects of minocycline and emdogain in the treatment of peri-implant mucosal inflammatio

Phase 2

• Conditions: mocusal inflammation around dental implants.; Sepsis due to anaerobes, Sepsis due to other Gram-negative organisms; A41.5, A41

• Registration Number: IRCT201311103690N4
• Lead Sponsor: Vice chancellor for research, Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

- Adults aged 18 years and older
- Patients with peri-implant inflammation, defined as: Presence of bleeding on probing, probing depth more than 4mm, lack of soft tissue recession, radio-graphic bone loss less than 2mm.
- Implant functioning for at least one year
Exclusion criteria:
- Taking systemic or local antibiotics in the past 3 months
- Regular intake of anti-inflammatory drugs in the past 3 months
- Any intervention for treatment of peri-implant inflammation in the past 3 months
- Poor oral hygiene
- Smoking
- Long term treatment with any medication that affects soft and hard tissue conditions (such as phenytoin, cyclosporin, calcium canal blockers...)
- Pregnancy and lactation
- Sever periodontal disease
- Uncontrolled diabetes or debilitating systemic disease
- Drug and alcohol addiction
- Allergy to tetracycline-class drug(s)

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umbers of the porphyromonas gingivalis bacteria. Timepoint: Before intervention, 2 weeks and 3 months after intervention. Method of measurement: The number of bacteria with polymerase chain reaction (PCR).